Can Memantine Cause Confusion in Elderly Patients?
Yes, memantine can cause confusion in elderly patients with dementia, and this is recognized as a significant adverse effect that may warrant discontinuation of the medication.
Evidence from Guidelines and FDA Labeling
The 2020 Canadian Consensus Conference on Dementia explicitly lists confusion as an intolerable side effect of memantine that should prompt consideration of discontinuation 1. The guideline specifically states that for individuals taking memantine for Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, or vascular dementia, discontinuation should be considered if there is "development of intolerable side effects (eg, confusion, dizziness, falls)" (Level 1C evidence, 96% consensus).
The FDA drug label for memantine confirms this risk, listing confusion among the most common adverse reactions (incidence ≥5% and higher than placebo) in double-blind placebo-controlled trials involving dementia patients 2. The FDA labeling explicitly states that confusion was one of the four most common adverse reactions alongside dizziness, headache, and constipation.
Clinical Trial and Research Evidence
Multiple research studies corroborate this finding:
A 2013 systematic review found that memantine significantly increased the risk of confusion compared to placebo in Alzheimer's disease patients 3
A 2009 review specifically identified confusion as one of the side effects that may occur during memantine treatment, noting these effects are typically mild and transient 4
A 2008 open trial in dementia with Lewy bodies reported that 2 patients were withdrawn from the study because of episodes of confusion during the titration phase 5
A 2004 review listed confusion among the adverse events associated with memantine use 6
A 2024 case report documented echolalia and altered mental status in an 86-year-old man with memantine overdose, highlighting the neuropsychiatric effects of this medication 7
Clinical Implications and Management
When to Consider Confusion as Drug-Related:
- New-onset confusion after memantine initiation or dose increase
- Confusion occurring during dose titration (particularly vulnerable period)
- Confusion in patients with severe renal impairment (dose reduction to 5 mg twice daily recommended) 2
- Confusion in context of memantine overdose (symptoms typically resolve within 100 hours, consistent with drug half-life) 7
Important Caveats:
The challenge in elderly dementia patients is distinguishing memantine-induced confusion from:
- Underlying disease progression (dementia itself causes confusion)
- Delirium from other causes (infection, metabolic disturbances)
- Polypharmacy effects (elderly patients often take multiple medications)
The Canadian guidelines emphasize that worsening should be assessed "in the absence of other medical conditions (eg, presence of delirium, significant concomitant medical illness) or environmental factors (eg, recent transition in residence)" 1.
Management Algorithm:
- If confusion develops during titration: Consider slowing titration or temporarily holding the medication
- If confusion occurs at therapeutic doses: Rule out other causes (delirium, infection, metabolic issues, drug interactions)
- If confusion is intolerable and attributable to memantine: Discontinue gradually (reduce dose by 50% every 4 weeks) 1
- Monitor for improvement: Confusion from memantine should improve after discontinuation
Special Populations at Higher Risk:
- Patients with severe renal impairment (requires dose reduction) 2
- Patients with severe hepatic impairment (use with caution) 2
- Patients taking medications that alkalinize urine (reduces memantine clearance by ~80%) 2
The bottom line: Confusion is a well-documented adverse effect of memantine that occurs more frequently than with placebo, is recognized by both regulatory agencies and clinical guidelines as grounds for discontinuation, and should be carefully monitored in elderly patients, particularly during dose titration and in those with renal impairment.